Search

cobas® Influenza A/B & RSV Assay

Deliver a differential diagnosis for influenza A, influenza B and RSV

Product image for cobas® Influenza A/B and RSV Assay
Differentiated influenza A/B and RSV testing in only 20 minutes

The young and old are particularly vulnerable to infection from respiratory syncytial virus (RSV). It is the leading cause of lower respiratory disease for children younger than 4 years, and globally, nearly all children are infected by age two.1 On the other side of the age continuum, RSV is also common in adults older than 65 and their risk of serious infection increases with age.2 Timely test results can help guide clinical response for infection management and control.

 

The cobas® Influenza A/B & RSV Nucleic acid test for use on the cobas® Liat® System is an automated multiplex real-time polymerase chain reaction (PCR) test that detects and differentiates influenza A, influenza B and RSV in just 20 minutes.

cobas® Influenza A/B & RSV performance3

Influenza A*
 

LOD: 2 x 10-3 – 2 x 10-2 TCID ­50/mL

Positive Agreement

SARS CoV flu AB graph C

(95% CI: 96.0% - 99.4%)

Negative Agreement

SARS CoV flu AB graph D

(95% CI: 95.4% - 97.3%)

Influenza B*
 

LOD: 2 x 10-3 – 4 x 10-3 TCID ­50/mL

Positive Agreement

SARS CoV flu AB graph E

(95% CI: 93.9% - 99.3%)

Negative Agreement

SARS CoV flu AB graph F

(95% CI: 98.9%-99.7%)

RSV*
 

LOD: 4 x 10-1 TCID ­50/mL

Positive Agreement

SARS CoV flu AB graph E

(95% CI: 94.5%-99.1%)

Negative Agreement

SARS CoV flu AB graph F

(95% CI: 97.6%-98.9%)

*Performance of the test was compared with an FDA-cleared, laboratory-based, multiplexed, real-time, reverse transcription PCR (RT-PCR) test across three targets.

CI=confidence intervals. LOD=limit of detection. TCID=tissue culture infective dose.

The cobas® Liat® PCR System vs. conventional methods

Influenza A/B rapid
antigen test

(Test 1 of 2)
Patient suspected of influenza

Patient suspected of influenza

Specimen collected to perform a rapid antigen test

Specimen collected to perform a rapid
influenza diagnostic test (RITD)

Negative result needs confirmation

Negative result needs confirmation.
Risk of delayed treatment decisions.

Samples sent to the lab for PCR testing

Samples sent to the lab for PCR testing (4-24 hours)

Patient less likely to benefit from antiviral treatment

Patient less likely to benefit from antiviral treatment
started >48 hours after symptom onset⁴

RSV rapid
antigen test

(Test 2 of 2)
Patient suspected of influenza

Patient suspected of RSV

Specimen collected to perform a rapid antigen test

Specimen collected to perform an RSV
rapid antigen diagnostic test (RADT)

Negative result needs confirmation

Negative result still leave unanswered questions.
Risk of delayed treatment decisions.

cobas® Influenza A/B
& RSV

(3 targets in 1 test)
Patient suspected of influenza

Patient suspected of influenza or RSV

Specimen collected

Specimen collected
 

Perform cobas® Influenza A/B Test

Perform cobas® Influenza A/B & RSV test
(Definitive results in 20 minutes)

Learn more about the expanding menu of assays

 
 
 
cobas® Liat® System

 

Rapidly test, triage, and treat your patients with the accuracy, simplicity, and security needed at the point of care.

Learn more
Drag Image to Rotate
360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list 360 degree images list

The cobas® Influenza A/B and RSV Nucleic acid test for use on the cobas® Liat® System (cobas® Influenza A/B & RSV) is an automated multiplex real-time RT-PCR assay for the rapid in vitro qualitative detection and discrimination of Influenza A virus, Influenza B virus and respiratory syncytial virus (RSV) RNA in nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors. The test is intended for use as an aid in the differential diagnosis of Influenza A, Influenza B, and RSV in humans and is not intended to detect Influenza C.

CE-IVD, FDA 510(k) cleared, CLIA waived

The cobas® Liat® System is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Access package inserts through your country’s Roche Diagnostics Website.

Young girl diagnosed with Influenza

Test for it. Don’t ignore it.

Respiratory

Respiratory tract infections

The non-specific clinical presentation of respiratory infections poses a considerable challenge to the differential diagnosis of pathogens. What impact can a timely and accurate diagnosis have on patient management?

Learn more
Healthcare associated infections

Healthcare-associated infections (HAIs)

From prolonging institutional stays to creating long-term disability, healthcare-associated infections place a tremendous financial burden on health systems.

Learn more
Antimicrobial resistance

Antibiotic resistance and diagnostic testing

As mankind continues its widespread use of antibiotics, antimicrobial resistance will continue to pose a threat to the global healthcare system.

Learn more

References

  1. Collins PL and Grahm BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol. 2008:82(5);2040-2055.
  2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults. NEJM. 2005:352(17);1749-59.
  3. cobas® Influenza A/B & RSV [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016.
  4. Centers for Disease Control and Prevention. Use of antivirals. http://www.cdc.gov/flu/professionals/antivirals/antiviral-use-influenza.htm. Accessed April 20, 2017.

Related products

RMD_cobas_liat_system
cobas® Liat® System
cobas infinity POC
cobas® infinity POC solution

Related assays

SARS_Influenza_AB
cobas® SARS-CoV-2 &
Influenza A/B Assay Molecular Diagnostics
Product image for cobas® Strep A Assay
cobas® Strep A Assay
Product image for cobas® Cdiff
cobas® Cdiff